The 2023 WCIRDC: Obesity
Zachary T. Bloomgarden,
Corresponding Author
Zachary T. Bloomgarden
Department of Medicine, Division of Endocrinology Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Correspondence
Zachary T. Bloomgarden, Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Email: [email protected]
Search for more papers by this authorZachary T. Bloomgarden,
Corresponding Author
Zachary T. Bloomgarden
Department of Medicine, Division of Endocrinology Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Correspondence
Zachary T. Bloomgarden, Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Email: [email protected]
Search for more papers by this authorFirst published: 23 April 2024
REFERENCES
- 1Brown KA, Scherer PE. Update on adipose tissue and cancer. Endocr Rev. 2023; 44(6): 961-974.
- 2Woolcott OO, Bergman RN. Relative fat mass (RFM) as a new estimator of whole-body fat percentage ─ a cross-sectional study in American adult individuals. Sci Rep. 2018; 8(1): 10980.
- 3Suthahar N, Wang K, Zwartkruis VW, et al. Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population. Eur J Intern Med. 2023; 109: 73-78.
- 4Mittendorfer B, Kayser BD, Yoshino M, et al. Heterogeneity in the effect of marked weight loss on metabolic function in women with obesity. JCI Insight. 2023; 8(12):e169541.
- 5Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018; 391(10120): 541-551.
- 6Ding C, Chan Z, Chooi YC, et al. Regulation of glucose metabolism in nondiabetic, metabolically obese normal-weight Asians. Am J Physiol Endocrinol Metab. 2018; 314(5): E494-E502.
- 7Sjöström L. Review of the key results from the Swedish obese subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013; 273(3): 219-234.
- 8Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023; 389(24): 2221-2232.
- 9 Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2): 145-154.
- 10Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018; 27(6): 1212-1221.e3.
- 11He M, Li B, Li M, Gao S. Does early time-restricted eating reduce body weight and preserve fat-free mass in adults? A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2024; 18(2):102952.
- 12Chen M, Xu L, Van Horn L, et al. Association of 8-Hour Time-Restricted Eating with All-Cause and Cause-Specific Mortality. Downloaded 3/19/24 from https://newsroom.heart.org/news/8-hour-time-restricted-eating-linked-to-a-91-higher-risk-of-cardiovascular-death
- 13Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. doi:10.1038/s41366-024-01473-y
- 14Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023; 402(10403): 720-730.
- 15Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024; 67(3): 470-482.
- 16Jastreboff AM, Kaplan LM, Frías JP, et al. Retatrutide phase 2 obesity trial Investigators. Triple-hormone-receptor agonist Retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023; 389(6): 514-526.
- 17Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 receptor agonist Orforglipron for adults with obesity. N Engl J Med. 2023; 389(10): 877-888.
- 18Knop FK, Aroda VR, do Vale RD, et al. OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10403): 705-719.
- 19Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024; 6(2): 290-303.
- 20Killion EA, Chen M, Falsey JR, et al. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nat Commun. 2020; 11(1): 4981.
- 21Tamaki N, Ahlholm N, Luukkonen PK, et al. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022; 132(21):e162513.
- 22Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF21 analogue Pegozafermin in NASH. N Engl J Med. 2023; 389(11): 998-1008.
- 23Harrison SA, Bedossa P, Guy CD, et al. Ratziu V; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl J Med. 2024; 390(6): 497-509.
- 24Li S, Duan F, Li S, Lu B. Administration of silymarin in NAFLD/NASH: a systematic review and meta-analysis. Ann Hepatol. 2024; 29(2):101174.
